Oct 15
Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication
Medical Devices
For Health Professionals
FDA Collaborates with Health Professional Societies, Trade Associations, and Academia
Topic Paragraphs
Call-To-Action Title
FDA Expert Panels
Call-To-Action Title
FDA Expert Panels
May 20, 2025 - “Expert Panels with the FDA” are a series of roundtable discussions to provide an open public discourse on the latest medical and scientific information on several important topics. At this roundtable, experts discussed health concerns related to the use of talc products.
Subscribe to our e-newsletter
We know you're busy! The easiest way to keep up with us is to subscribe to our weekly e-newsletter.
You'll get the latest announcements, regulations, and upcoming events delivered to your email inbox every Monday.
How to Report Adverse Events to FDA MedWatch
Health professionals, consumers and patients can voluntarily report observed or suspected adverse events for human medical products to FDA. Voluntary reporting can help FDA identify unknown risk for approved medical products.
Learn MoreMedWatch Safety Alerts
Oct 10
FDA Approves Labeling Changes that Include a Boxed Warning for Immune Effector Cell-associated Enterocolitis Following Treatment with Ciltacabtagene Autoleucel (CARVYKTI, Janssen Biotech, Inc.)
Biologics
Oct 10
Alert: Automated Impella Controller Correction due to Cybersecurity Issue from Abiomed
Medical Devices
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
FDA Encourages Development of New, Reliable Alternatives to Animal Testing in Sunscreen
FDA strongly encourages companies to continue to develop new, reliable ways to minimize animal testing.
FDA Focuses on Closing the Clinical Trial Reporting Gap for Research Integrity
The FDA is committed to ensuring data transparency by promoting timely registration and reporting of results information to ClinicalTrials.gov.
FDA Advances Drug Development Innovation by Establishing ISTAND as Permanent Qualification Program
ISTAND supports innovative, science-driven approaches that improve drug development and regulatory decision-making.
Reach out today to talk about collaborating!
Public Engagement Staff
Office of External Affairs
Office of the Commissioner
Food and Drug Administration
10903 New Hampshire Ave WO32-5367
Silver Spring, MD 20993
United States
Office of External Affairs
Office of the Commissioner
Food and Drug Administration
10903 New Hampshire Ave WO32-5367
Silver Spring, MD 20993
United States
Hours Available
Public Engagement Staff
Paragraph Header (Column 2)
MedWatch Safety Alerts on X:
Paragraph Header (Column 2)
MedWatch Safety Alerts on X:
MedWatch
FDA MedWatch Safety Information
You know the moment it happens.
Follow @FDAMedWatch